Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 1079 • 2016 ACR/ARHP Annual Meeting
Discovery of Novel Autoantigens in Sjogren’s Syndrome with Potential for Subgrouping of Disease
Peter Schulz-Knappe¹, Petra Budde¹, Hans-Dieter Zucht¹, Heike Göhler¹, Klaus Marquart¹, Prof. Dr. Matthias Schneider² and Torsten Witte³, ¹Protagen AG, Dortmund, Germany, ²Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany, ³Department of Clinical Immunology and Rheumatology, Hannover Medical School, Hannover, Germany
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a common autoimmune disease with exocrine gland dysfunction and multi-organ involvement. With the growing interest in conducting clinical trials…
Abstract Number: 2673 • 2016 ACR/ARHP Annual Meeting
Glandular Ultrasonography in Primary SjöGren Syndrome: Clinical and Laboratory Correlation
Tania Fidelix¹, Virginia Trevisani², Adagmar Andriolo³ and Adriano Czapkowski⁴, ¹Evidence Based Medicine, Federal University of Sao Paulo, Sao Paulo, Brazil, ²Health Evidence Based, Escola Paulista de Medicina, São Paulo, Brazil, ³Clinical Laboratories, Escola Paulista de Medicina, Sao Paulo, Brazil, ⁴Radiology, Radiology Department- Escola Paulista de Medicina, Sao Paulo, Brazil
Background/Purpose: Primary SjogrenÕs syndrome (pSS) is a chronic autoimmune disorder that is characterized clinically by dryness of the eyes (xerophthalmia) and mouth (xerostomia). The assayÕs…
Abstract Number: 3228 • 2016 ACR/ARHP Annual Meeting
Specific T Cell and B Cell Distributions Characterize Subgroups of Patients with Primary Sjögren’s Syndrome and Are Associated with Disease Activity and Pro-Inflammatory Cytokine Expression
Lucas Le Lann¹, Quentin Simon¹, Christophe Jamin¹, Maria Orietta Borghi², Lorenzo Beretta³, Ricard Cervera⁴, Alain Saraux⁵, Divi Cornec¹, Rik Lories⁶, Carlo Chizzolini⁷, Marta E. Alarcon Riquelme⁸, Jacques-Olivier Pers¹ and on behalf of the PRECISESADS Consortium, ¹INSERM ERI29, EA2216, Université de Brest, Labex IGO, CHRU Morvan, Brest, France, ²University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, ³Rheumatology, Milan, Italy, ⁴Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, KU Leuven and University Hospitals Leuven., Leuven, Belgium, ⁷University hospital of Geneva, Geneva, Switzerland, ⁸Centro de Genomica e Investigación Oncológica, Pfizer-University of Granada-Junta de Andalucía, Granada, Spain
Background/Purpose : The goal of the IMI PRECISESADS project is to reclassify individuals affected by systemic autoimmune diseases (SADs) into clusters of molecular, instead of…
Abstract Number: 184 • 2016 ACR/ARHP Annual Meeting
Upregulation and Activation of the IFI16-Sting-IRF3-IFN Pathway in Sjogren’s Salivary Glands
Brendan Antiochos¹, Livia Casciola-Rosen² and Antony Rosen³, ¹Rheumatology, Johns Hopkins University School of Medicine, Maltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Type I IFN expression is known to be upregulated in the salivary glands of patients with SjogrenÕs syndrome, but the upstream stimuli responsible for…
Abstract Number: 1080 • 2016 ACR/ARHP Annual Meeting
B-Cell Clonal Expansions in Parotid Glands of Sjogren’s Patients Are Associated with Increased Numbers of N-Glycosylation Motifs in the Immunoglobulin Heavy Chain Genes
Annie Visser¹, Marieke E. Doorenspleet², Niek de Vries³, Fred K.L. Spijkervet⁴, Arjan Vissink⁵, Hendrika Bootsma⁶, Frans G.M. Kroese¹ and Nicolaas A Bos¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Dept. of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by chronic inflammation of salivary and lacrimal glands. Patients with pSS have increased clonal…
Abstract Number: 2676 • 2016 ACR/ARHP Annual Meeting
Changes in Salivary Gland Echostructure in Patients with Primary SjöGren’s Syndrome over the Time: A Four-Year Longitudinal Study
Chiara Baldini¹, Nicoletta Luciano², Francesco Ferro³, Elena Elefante³, Stefano Bombardieri³ and Marta Mosca⁴, ¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ²Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Clinical and Experimental Medicine, University of Pisa, Rheumatology Unit, Pisa, Italy
Background/Purpose: Salivary gland ultrasonography (SGUS) has recently appeared as a promising tool for a non-invasive diagnosis of primary Sjögren’s syndrome (pSS). However, it is still…
Abstract Number: 3229 • 2016 ACR/ARHP Annual Meeting
Bone Morphogenetic Protein 6 Receptor Inhibition Restores Salivary Gland Function in a Mouse Model of Primary Sjögren’s Syndrome
Hongen Yin¹, Lovika Kalra¹, Arif Karim¹, Zhennan Lai¹, Maria Guimaro¹, Lauren Aber¹, Bill Swaim¹, Sandra Afione¹, Alexandria Voigt², Cuong Nguyen³, Paul Yu⁴, Donald Bloch⁵ and John A. Chiorini¹, ¹Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ²Department of Pathology and Infectious Diseases, University of Florida, Gainesville, FL, ³Department of Pathology and Infectious Diseases, University of Florida, Bethesda, MD, ⁴Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵Center for Immunology and Inflammatory Diseases and the Division of Rheumatology, Allergy, and Immunology of the Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Methods: Results: Elevated BMP6 was found in 63/80 (78.8%) of pSS patients examined in this study. In humans, ALK2 and ALK3 receptors…
Abstract Number: 340 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine: A Potential Treatment for Osteoporosis By Osteoclast Inhibition!
Tim Both¹, Paul L. van Daele² and Bram Van der Eerden¹, ¹Internal Medicine, Erasmus MC, Rotterdam, Netherlands, ²Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: We recently showed that patients with primary Sjögren Syndrome (pSS) have significantly higher bone mineral density (BMD) in the lumbar spine and femoral neck…
Abstract Number: 1216 • 2016 ACR/ARHP Annual Meeting
Sjogren’s Syndrome-Associated Transcripts Show Correlation with Objective Measures of Dryness
John A. Ice¹, Indra Adrianto¹, Astrid Rasmussen¹, Kiely Grundahl², Michelle L. Joachims³, Graham B. Wiley¹, Jennifer A. Kelly¹, Glen D. Houston⁴, David M. Lewis⁴, Lida Radfar⁵, Donald U. Stone^6,7, Barbara M. Segal⁸, Nelson L. Rhodus⁹, Joel M. Guthridge³, James Chodosh^10,11, Raj Gopalakrishnan¹², Andrew J.W. Huang¹³, Pamela J Hughes¹⁴, Michael D. Rohrer¹⁵, Judith A. James^1,16,17, Courtney G. Montgomery¹, R. Hal Scofield^1,17,18, Patrick Gaffney¹, Kathy L. Sivils³ and Christopher J. Lessard¹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Oral and Maxillofacial Pathology, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁵Oral Diagnosis and Radiology Department, University of Oklahoma College of Dentistry, Oklahoma City, OK, ⁶King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia, ⁷Department of Ophthalmology, Johns Hopkins University, Baltimore, MD, ⁸Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ⁹Department of Diagnostic and Biological Sciences, University of Minnesota School of Dentistry, Minneapolis, MN, ¹⁰Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, ¹¹Harvard Medical School, Boston, MA, ¹²Diagnostic and Biological Sciences, Division of Oral Pathology, University of Minnesota School of Dentistry, Minneapolis, MN, ¹³Department of Ophthalmology and Visual Sciences, Washington University, St. Louis, MO, ¹⁴Department of Oral and Maxillofacial Surgery, Oregon Health & Science University School of Dentistry, Portland, OR, ¹⁵Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ¹⁶Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁷Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁸US Department of Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disorder in which exocrine dysfunction can lead to chronic, debilitating dryness. Expression studies in SS have identified…
Abstract Number: 2681 • 2016 ACR/ARHP Annual Meeting
Clinical and Immunological Characteristics of Primary Sjogren´s Syndrome in Men
Rebeca Belmonte¹, Carlos Sánchez-Piedra², Monica Fernandez Castro³, Jose Luis Andreu⁴, Victor Martinez Taboada⁵, Alejandro Olivé⁶, José Rosas⁷, Jorge González Martín⁸, Esther Ruiz Lucea⁹, Antonio Naranjo¹⁰, Oscar Illera¹¹, Lurdes Romani¹², Sheila Melchor¹³, Begoña Moreira¹⁴, Enrique Raya¹⁵, Marina Rodriguez¹⁶, Natalia Cid¹⁷ and on behalf of SJOGRENSER project (GEEAS-SER), ¹Rheumatoloy, Hospital Virgen de la Salud, Toledo, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ³Rheumatology, Hospital Infanta Sofía, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁵Hospital Marqués de Valdecilla., Santander, Spain, ⁶Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁷Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁸Rheumatology, Hospital Madrid Norte Sanchinarro, Madrid, Spain, ⁹Rheumatology, Hospital de Basurto, Bilbao, Spain, ¹⁰Rheumatology Division, Hospital Doctor Negrin, Las Palmas GC, Spain, ¹¹Rheumatology, Hospital Universitario Infanta Sofía, Madrid, Spain, ¹²Hospital Virgen de las Nieves., Granada, Spain, ¹³Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁴Rheumatology, Hospital de Sierrallana, Torrelavega, Spain, ¹⁵Rheumatology Department, Hospital Clínico San Cecilio, Granada, Spain, ¹⁶Rheumatology, University Hospital Complex of Vigo, Vigo, Spain, ¹⁷Rheumatology, Hospital de Valme, Sevilla, Spain
Background/Purpose: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease involving primarily the exocrine glandular system. pSS in men is uncommon. Data of pSS in…
Abstract Number: 3239 • 2016 ACR/ARHP Annual Meeting
Expression of IFN-Regulated Genes in Autoantibody Exposed Babies in Utero
Malin Hedlund¹, Gudny-Ella Thorlacius¹, Margarita Ivanchenko¹, Vijole Ottosson¹, Amina Ossoinak¹, Linda Lagnefeldt¹, Joanna Tingstrom¹, Alexander Espinosa¹, Lars Rönnblom², Maija-Leena Eloranta², Sven-Erik Sonesson¹ and Marie Wahren-Herlenius³, ¹Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Stockholm, Sweden, ²Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, ³Department of Medicine, Solna, Unit of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Ro/SSA autoantibodies and an IFN signature are commonly present in women with Sjögren’s syndrome and SLE. During pregnancy, the autoantibodies are transported across the…
Abstract Number: 11L • 2015 ACR/ARHP Annual Meeting
Preliminary Results of a Double-Blind Randomised Trial of Rituximab Anti-B-Cell Therapy in Patients with Primary Sjogrens Syndrome
Simon Bowman¹, Colin Everett², Michele Bombardieri³, Robert Busch⁴, Paul Emery⁵, Frances Hall⁶, Colin T. Pease⁷, Costantino Pitzalis⁸, Elizabeth Price⁹, Luke Dawson¹⁰, Peter Smith¹¹, Nurhan Sutcliffe³, Wan-Fai Ng¹², Catherine Fernandez¹³, Sharon Ruddock¹³, Linda Sharples¹³, Catherine Reynolds¹³ and Sue Pavitt¹⁴, ¹Rheumatology Dept, University Hospital Birmingham, Birmingham, United Kingdom, ²Leeds Institute for Clinical Trials Research, University of Leeds, LEEDS, United Kingdom, ³Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ⁴Department of Life Sciences, University of Roehampton, London, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds Gen Infirmary, Leeds, United Kingdom, ⁶School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom, ⁷Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁸Centre for Experimental Medicine & Rheumatology, Queen Mary's School of Medicine and Dentistry, London, United Kingdom, ⁹Rheumatology Department, Great Western Hospital, Swindon, United Kingdom, ¹⁰School of Dental Sciences, University of Liverpool,, Liverpool, United Kingdom, ¹¹School of Dental Sciences,, University of Liverpool, Liverpool, United Kingdom, ¹²NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, United Kingdom, ¹³Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, United Kingdom, ¹⁴Division of Applied Health & Clinical Translation , School of Dentistry, University of Leeds, Leeds, United Kingdom
Background/Purpose: Evidence from open-label and observational studies support anti-B-cell therapy in patients with primary Sjogren’s Syndrome (PSS). The TRACTISS trial aimed to determine the extent…
Abstract Number: 636 • 2015 ACR/ARHP Annual Meeting
Utility of IgA Anti-Alpha-Fodrin Antibodies in Combination with Rheumatoid Factor and/or Antinuclear Antibodies As Substitute Immunological Criterion for Sjögren’s Syndrome
Gabriela Hernandez-Molina¹, Carlos Núñez-Álvarez², Juanita Romero-Diaz¹, Carmen Ávila-Casado³, Carlos Hernández-Hernández⁴, Maria Luisa Calderillo⁴, Martha Marroquín⁴, Claudia Recillas-Gispert⁵ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Pathology, University Health Network, Toronto Canada., Toronto, ON, Canada, ⁴Dental Service, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁵Ophtalmology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: Anti-SSA/SSB antibodies represent the most specific serologic marker of Sjögren’s syndrome; however, in up to 30% of SS patients the test is negative.…
Abstract Number: 1363 • 2015 ACR/ARHP Annual Meeting
Changes in Cyclooxygenase-2’s Expression, and PGE2’s and 6-Keto-PGF1α Levels in the Presence of the Muscarinic Acethylcholine Receptor Antibody in Primary Sjogren Syndrome
Micaela Ana Cosatti¹, Silvia Reina², Cecilia N. Pisoni³, Alicia Eimon⁴, Sabrina Ganzinelli² and Enri Borda², ¹Section Rheumatology and Immunology, CEMIC, CABA, Argentina, ²Pharmacology Unit, School of Dentistry, University of Buenos Aires, Buenos Aires, Argentina; National Research Council of Argentina (CONICET), Buenos Aires, Argentina, ³Lupus Research Unit, The Rayne Institute, St Thomas' Hospital and Kings College London, London, United Kingdom, ⁴CEMIC, Buenos Aires, Argentina
Background/Purpose: to assess the inflammatory process provoked by the M3 muscarinic acetylcholine receptor antibody from primary Sjogren Syndrome (pSS) patient’s sera in rat submandibular gland…
Abstract Number: 2798 • 2015 ACR/ARHP Annual Meeting
Increased Frequency of the PTPN22W* Variant in Primary Sjögren’s Syndrome-Association with Low Type I IFN Scores in Peripheral Blood
Nikolaos Vlachogiannis¹, Eliona Gkioka², Adrianos Nezos³ and Clio Mavragani⁴, ¹Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ²Physiology, Department of Experimental Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ³Physiology, Department of Experimental Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, ⁴Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Protein tyrosine phosphatase non-receptor 22 (PTPN22) gene encodes a protein tyrosine phosphatase previously shown to inhibit antigen-receptor signaling in T cells and promoting type…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].